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Background: In recent decades it has been noted that trained dogs can detect specific odor molecules emitted by
cancer cells. We have shown that the same odor can also be detected in the patient’s blood with high sensitivity
and specificity by trained dogs. In the present study, we examined how the ability of dogs to detect this smell was
affected by treatment to reduce tumor burden, including surgery and five courses of chemotherapy.
Methods: In Series I, one drop of plasma from each of 42 ovarian cancer patients (taken between the fifth and
sixth courses of chemotherapy) and 210 samples from healthy controls were examined by two trained dogs. All 42
patients in Series I had clinical complete responses, all except two had normal CA-125 values and all were declared
healthy after primary treatment. In Series II, the dogs examined blood taken from a new subset of 10 patients at 3
and 6 months after the last (sixth) course of chemotherapy.
Results: In Series I, the dogs showed high sensitivity (97%) and specificity (99%), for detecting viable cancer cells or
molecular cancer markers in the patients’ plasma. Indeed, 29 of 42 patients died within 5 years. In Series II, the dogs
indicated positive samples from three of the 10 patients at both the 3- and 6-month follow-up. All three patients
had recurrences, and two died 3–4 years after the end of treatment. This was one of the most important findings
of this study. Seven patients were still alive in January 2013.
Conclusions: Although our study was based on a limited number of selected patients, it clearly suggests that
canine detection gave us a very good assessment of the prognosis of the study patients. Being able to detect a
marker based on the specific cancer odor in the blood would enhance primary diagnosis and enable earlier relapse
diagnosis, consequently increasing survival.
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During the past two decades, an increasing number of
authors have described cancer detection by dogs trained
on various biological materials such as urine, breath, and
stool [1-3]. Pickel [4] was the first to use tumor tissue
from melanoma in the training of such dogs, and to our
knowledge we are the only researchers to have used tis-
sue from ovarian carcinomas or blood of patients with
ovarian cancer [5,6]. We have previously shown that the
odor emitted by cancer cells is also present in patients’* Correspondence: gyorgy.horvath@oncology.gu.se
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reproduction in any medium, provided the orblood, and that trained dogs can detect it with high sensi-
tivity and specificity [6]. We have also shown that dogs
trained to recognize the odor of ovarian cancer could not
recognize odors from other gynecological malignancies
[5,6]. In addition, the dogs could not distinguish among dif-
ferent histopathological subgroups, stages or grades of ovar-
ian carcinomas (including borderline tumors). The fact that
the dogs could not recognize cancers other than ovarian
cancer strongly suggests that different cancers have differ-
ent characteristic smells, thus enabling both diagnosis and
differential diagnosis. Moreover, the characteristic odor of
ovarian carcinoma is likely organ-specific [5].
In addition to trained dogs, researchers have also used
electronic noses to detect cancer-related volatile organicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Horvath et al. BMC Cancer 2013, 13:396 Page 2 of 7
http://www.biomedcentral.com/1471-2407/13/396compounds in the headspace above malignant tissues
[7,8]. These detection methods, however, had relatively
low sensitivity and were not shown to be tumor-specific
as the only comparisons made were versus healthy mater-
ial. In their current form, electronic devices probably lack
the sensitivity to distinguish a specific cancer from other
cancers, which is a crucial requirement for practical use.
This specific odor of carcinomas is thus an important
characteristic that is likely to play an important role in future
early cancer diagnosis and also in disease monitoring. Our
previous work [5,6] was based on tissue samples taken at
primary surgery or blood taken before or immediately after
surgery; the aim of those studies was primarily to investigate
the possibility of using odor for screening and diagnosis of
ovarian cancer. However, it may be useful to see how pri-
mary treatment (via the influence on tumor status) changes
the production of cancer odor molecules. These changes
may be mediated by various factors such as tumor burden,
changes in malignant cell metabolism, tumor necrosis. In
the future, the answer to this question may be crucial for
odor-based monitoring in the follow-up of cancer.
The aim of the present study was to investigate how
primary surgery and chemotherapy treatment affected
the diagnosis of cancer odor in the blood of patients
with different life expectancies based on their initial
diagnosis. The study was conducted using two specially
trained dogs that were used in our previous studies [6].
Methods
Ethics
This study was conducted in accordance with regulations
of the Helsinki Declaration (1964) and conforms to the
Regional Ethics Committee, Gothenburg.
Dogs
Two dogs were used, Hanna, a 10-year-old black Giant
Schnauzer (chip no. 967000000389928), and Lotti, a 6-year-
old black Giant Schnauzer (chip no. 098100311386). The
owner and handler is GH. The dogs live as family pets with
the owner and his family. There is free access to fresh water
all day, and feeding three times a day. The dogs spend sev-
eral hours each day in a garden or on walks. Health checks
are made at Värmdö Animal Clinic, Gustavsberg.
Training
The training method has been described in detail else-
where [5,6]. For 2 years prior to the present study, only
once-a-week maintenance training was used. Each of the
training sessions included 4–10 boxes [5], 0–3 of which
contained cancer tissue or blood from patients with
ovarian carcinoma. The setup was randomly selected
before each session. This program allowed the dogs to be
confronted with a different problem to solve in each train-
ing occasion. The dogs were rewarded only for a correctidentification. Blood samples with >500 U/ml CA-125
values as an indicator of ovarian carcinoma [9] were used
for training. One drop of the training sample was placed in
a small plastic dish inside each box. The blood samples
used during the training period were not used in the tests.
The dogs were used in the experiment with the permission
of the Regional Ethical Review Board in Gothenburg, li-
cense number: S-220-08. The dogs had free access to fresh
water during training and testing hours. After 2 hours of
work, the dogs were walked or had 20 minutes of free time.
Patient selection
Patients were selected for inclusion in this retrospective
study from the clinic and bio-bank databases. The latter
contains blood and cancer tissue from patients with
ovarian cancer. Material was collected after obtaining
permission from the individual patient and was regu-
lated by the treatment program for ovarian cancer in
West Sweden. Patient selection first was made from the
clinic database, then the results were correlated with the
bio-bank database to obtain blood samples.
The major selection criterion applied to all study patients
was clinical complete remission (CR) before the sixth (final)
scheduled chemotherapy course. Patients selected for Series
I were divided into 3 groups. Group A, included patients
with 3 years of relapse-free survival, Group B included pa-
tients who had relapsed within 6 months after the last treat-
ment session; and for Group C included patients who had
relapsed between 1 and 2 years after treatment. A total of 66
patients with CR in the years 2001–2007 were selected in
Series 1. All were from the Gothenburg area and were also
in the bio-bank database. Forty-two patients had samples in
a biobank corresponding to one of the three secondary se-
lection criteria for inclusion in Group A, B or C. Selection
for Series II was made using the biobank database only.
Blood samples
Blood samples were collected from patients living in the
Gothenburg area of West Sweden. The population is
about 600,000. The treatment program for ovarian cancer
in requires CA-125 analysis on two occasions. First, prior
to or directly after primary surgery, and the second before
the sixth course of chemotherapy treatment. However, as
usual in the treatment program for ovarian carcinoma,
CA-125 level was not included in the follow-up, although
doctors have the option to check it. Blood samples
with >500 U/ml CA-125 values were used for dog training,
with one drop being placed in a small plastic dish inside
each box. Blood samples used during the training period
were not used in the tests.
Reference blood samples
Material for the reference group was selected from the
bio-bank database. Clinicopathological variables were
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showed that they did not affect the dogs’ sensitivity of
detection [5,6]. A total of 62 samples (42 for Series I
and 20 for Series II), from different individuals, with
CA-125 values >200 U/ml were randomly selected as
reference material in Series I and II.
Test blood samples in Series I
Forty-two samples were collected and used as test material
in Series I. These blood samples were taken before the sixth
course of chemotherapy. Patients were divided into three
groups. Group A consisted of 13 patients who had a
CR, 3-year relapse-free survival, and normal (<35 U/ml)
CA-125values before their last treatment course. Group B
consisted of 12 patients who had a CR, relapsed within
6 months, and all except 2 (61 U/ml; <200 U/ml) had
CA-125 <35UI. Group C consisted of 17 patients with
a CR, recurrence between 1 and 2 years, and normal
CA-125 values. Tumor histopathology, stage and grade
varied within the groups.
Blood samples with >500 U/ml CA-125 values were
used for training, with one drop being placed in a small
plastic dish inside each box. Blood samples used during
the training period were not used in the tests.
Test blood samples in Series II
Samples were taken 3 and 6 months after the sixth, final
chemotherapy course. Unfortunately, we could not follow
patients in Series I, Group A because none of them had
blood in the blood bank. We collected blood from 10 other
patients who were followed regularly. Median donor age
was 65 years (range, 38–78 years).
Control blood samples
Control samples were collected during the 2 years be-
tween 2007 and 2009, mostly from female medical staff
volunteers in Gothenburg. Inclusion criteria were that
the patients felt healthy, were not pregnant and were
free of gynecological disease. Control and test materials
were not age-matched. Younger persons were consciously
chosen as the source of control samples to reduce the risk
of the presence of asymptomatic of ovarian cancer. Thus,
both the control and test groups had samples from pre-and
postmenopausal women.
Sample preparation
Blood samples were collected in EDTA tubes, and then
centrifuged at 3000 rpm for 10 min with plasma pots
over the small plastic tubes. After centrifugation, the
plasma was divided into two parts, one for CA-125
analysis and the other for subsequent experiments.
The latter part was kept at −80°C in the tumor bank
(Ethical Committee license number: S-220-08, Regional
Ethical Review Board in Gothenburg). Control plasmasamples were processed and stored identically to the tar-
gets. However, tubes with control blood were stored separ-
ately. Median donor age was 45 years (range, 29–65 years).
Test design
Tests were carried out in a double-blind fashion as pre-
viously described [6]. To summarize, both test leader
and handler were blinded to the location of the target
samples, and were present in the test location only when
the dogs were working. The dogs were tested in two
series. Series I covered 4 days (2 days per occasion),
while Series II covered 2 days. Ten runs were performed
on each day, except for one day in Series I when 11 runs
were carried out. Each run included seven boxes, placed
in a circle about 2 m apart from each other. Each box
[5,6] contained a drop of plasma; five contained control
materials, one contained a test sample, and one contained
a reference sample. Reference materials were taken before,
or shortly after the primary operation, and thus had a high
concentration of odor molecules. The placement of the
target and reference boxes was changed by an assistant
between each run. Each box was cleaned with alcohol
between runs. The tests were documented on paper and
DVD by the test leader and one assistant [6].
Dog responses
A positive response was defined as indicating the target
box by scratching with the foreleg, lying down and
sniffing it (and not indicating the control samples). A
negative response was defined as sniffing and indicating
a control box and not indicating the target. An uncertain
response was defined as stopping at the box, smelling it,
scratching at it, and possibly barking, but going straight
on and not lying down.
Treatment of ovarian carcinomas
In line with the standard treatment program in West
Sweden, patients were treated by total hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, multiple
peritoneal biopsies, and peritoneal washings with cytology.
Approximately 4 weeks after primary surgery the first
carboplatin, cyclophosphamide, and epirubicin combin-
ation was given. A total of six courses were administered
at 4-week intervals.
Statistical methods
The raw data were summarized as sensitivity (the condi-
tional probability of the dog indicating cancer when the
condition was present) and test specificity (the conditional
probability of the dog ignoring a sample from a healthy
donor). Sensitivity and specificity give insight into the
general classification ability of the dogs.
The positive and negative predictive probability that the
test would give the correct diagnosis were also calculated.




Sensitivity 0.976 0.908 0.995
Specificity 0.995 0.980 0.999
For any particular test result, the probability that it will be:
Positive 0.166 0.135 0.202
Negative 0.833 0.797 0.864
For any particular positive test result, the probability that it is:
True positive 0.976 0.908 0.995
False positive 0.023 0.004 0.091
For any particular negative test result, the probability that it is:
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vals [10]. Both sensitivity and specificity were expressed as
proportions, thus standard techniques for proportions
could be applied for statistical inference. Confidence inter-
vals were based on the normal approximation, p 1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p 1−pð Þ=np where p is the estimated sensitivity, respective
specificity and n is the number of test runs.
The test runs are best described as having a
hypergeometric distribution. The probability of a per-
fect test run (i.e., finding the test sample and ignoring
the controls) by chance was 1/6, and the probability of
performing all the runs without making any errors follows
the binomial distribution. Reference samples were not
included in the statistical analyses.True negative 0.995 0.980 0.999
False negative 0.004 0.000 0.0190Results and discussion
Series I
Between them, the dogs correctly indicated all 42 refer-
ence samples, giving a sensitivity of 100%. Lotti cor-
rectly indicated 41 of the 42 test samples and wrongly
indicated 2 of the 210 controls, giving a sensitivity of
97% and a specificity of 99%. Hanna correctly indicated
41 of the 42 test samples and made no erroneous iden-
tifications among the controls, giving a sensitivity of
97% and a specificity of 100% (Table 1). The combined
results for both dogs showed a sensitivity of 97% and a
specificity of 99% (Table 2).
Each dog missed one test sample—one from Group B
and one from Group C; both patients died of cancer—
but still had a generally high sensitivity and specificity.
There should be no doubt in assuming that, in the majority
of patients, the number of characteristic odor molecules
would have been limited compared with the reference ma-
terial, and that it was this that led to the failures to identify
test samples. In contrast, the dogs identified all reference
samples correctly.
It is likely that the completion of surgery and chemother-
apy reduced the number of cancer cells in the patients’
bodies, thereby reducing the number of odor molecules in
their blood. Moreover, it seems likely that there were large
individual quantitative differences in characteristic odor
molecules in different samples. There will have been a wideTable 1 Dogs responses
Series I
Ref. Cancer Control Ref.
Lotti Yes 42 41 2 10
No 0 1 208 0
Hanna Yes 42 41 0 10
No 0 1 210 0
Ref.: reference samples.range in the number of molecules in the samples, but the
dogs were unable to signal quantitative differences; all
they could do was to signal a positive or a negative re-
sult. However, the results are interesting because there
were a number of patients who had radical surgery and
subsequently received five courses of chemotherapy.
All patients had clinical CR before the sixth course, as
evaluated by palpation under general anesthesia and in
some cases completed with a CT scan, and all except
two had normal CA-125 values.
Generally, doctors do not know how many patients
will have residual cancer cells after complete clinical re-
mission is declared, and it is unknown whether the final
treatment after this will kill any remaining cells. In fact,
our results suggest that almost all of the patients in our
study had viable cancer cells, and the majority (n=29) of
the 42 patients died of their disease. In Group A, two
patients died of intercurrent disease, one of ovarian carcin-
oma between 4 and 5 years after the treatment was fin-
ished, and one died of probable cancer, although without a
diagnosed relapse. Nine patients survived until the 5-year
follow-up. One of the dead patients in Group A had stage
I/A, two had stage I/C and the fourth had Stage III. Of theSeries II (3 m) Series II (6 m)
Cancer Control Ref. Cancer Control
6 2 10 6 5
4 48 0 4 45
8 3 10 10 3
2 47 0 0 47
Table 3 Sensitivity and specificity measures in Series II,
3 months (both dogs together)
Estimate 95% CI
Lower Upper
Sensitivity 0.7 0.456 0.871
Specificity 0.95 0.881 0.981
For any particular test result, the probability that it will be:
0.158 0.100 0.238
Negative 0.841 0.7612 0.899
For any particular positive test result, the probability that it is:
True positive 0.736 0.485 0.898
False positive 0.2631 0.101 0.514
For any particular negative test result, the probability that it is:
True negative 0.940 0.870 0.975
False negative 0.059 0.024 0.129
Table 4 Sensitivity and specificity measures in Series II,
6 months (both dogs together)
Estimate 95% CI
Lower Upper
Sensitivity 0.8 0.557314 0.933894
Specificity 0.92 0.843855 0.962321
For any particular test result, the probability that it will be:
Positive 0.2 0.134742 0.284927
Negative 0.8 0.715073 0.865258
For any particular positive test result, the probability that it is:
True positive 0.666667 0.446926 0.835734
False positive 0.333333 0.164266 0.553074
For any particular negative test result, the probability that it is:
True negative 0.958333 0.890714 0.986569
False negative 0.041667 0.013431 0.109286
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I/A, and three had Stage I/B.
In Group B, all patients died within 2 years. In this
group one patient had stage I/A, one had I/C and the
remaining patients had stage III–IV. In Group C, one
patient survived for 4 years relapse-free, but was then
lost to follow-up. The remaining 16 patients died be-
tween 16 months and 5 years after the end of treatment.
Two patients had stage I/C, one had IIB and 12 patients
had Stage III or IV. A patient who was lost to follow-up
had stage III disease.
We do not have information on clinicopathological
features such as stage, tumor grade, histology, age and
menopausal status of the individual patients included
in Series I. However, our previous studies [5,6] clearly
showed that when dogs were trained to recognize the
smell of ovarian cancer, those variables did not affect
sensitivity. Furthermore, although the study shows
detection of cancer odor to be a very good prognostic
factor, depending on the size of the group and the material
selected, comparison with other known prognostic factors
cannot be done.
On the other hand, it is also possible that surviving pa-
tients had residual living cancer cells between their fifth
and sixth courses of treatment, but far fewer cells than
patients who died of their disease, and the odor mole-
cules from those cells were detected by the dogs.
It is difficult to discuss our results on a broader basis,
because to our knowledge there are no other published
studies that have used blood samples with trained dogs
and related the findings to survival. However, our results
strongly suggest a great need for a more sensitive marker
than is currently available to ensure the safety of patients
and increase the overall survival of ovarian cancer patients.
Series II
All 20 reference samples were correctly indicated by both
dogs, giving a sensitivity of 100%.
Three-month test samples
Lotti correctly indicated six of 10 test samples (one of
which was uncertain) and wrongly indicated two of 50
controls, giving a sensitivity of 60% and a specificity of
96%. Hanna correctly indicated eight of 10 test samples
(one of which was uncertain) and wrongly indicated three
of 50 controls, giving a sensitivity of 80% and a specificity of
94% (Table 1). The combined results for both dogs showed
a sensitivity of 70% and a specificity of 95% (Table 3).
Six-month test samples
Lotti correctly indicated six of 10 test samples (one of
which was uncertain) and wrongly indicated five of 50
controls, giving a sensitivity of 60% and a specificity
of 90%. Hanna correctly indicated all 10 test samples(although four of the 10 selections were uncertain),
and wrongly indicated three of 50 controls, giving a
sensitivity of 100% and a specificity of 94% (Table 1).
The combined results for both dogs showed a sensitivity
of 80% and a specificity of 92% (Table 4).
During the 2-day test for Series II, both dogs appeared
to be under stress and generally unsettled; they barked,
made various unusual sounds, and often turned back
and tried to go in the opposite direction between the
boxes. We suspected that this could have been due to an
unusually low concentration of odor molecules in the
test samples. We tested the dogs in the interval between
the 2 test days without a test sample in the arrangement,
and they performed the search as usual. The following
day, when the test samples were included again, the anxious
and insecure behavior returned. However, the fact that
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the specificity was high (as it was in our previous studies)
suggests that the overall results are correct.
We selected samples from patients who were relapse-
free during the first 3 years after treatment. This choice
of time period was based on the fact that most recur-
rences are diagnosed in the first 3 years [11]. Patients
were selected from our database and since the disease
may relapse even after the first 3 years after treatment,
we also checked the patient case records in January 2013
(Table 5). The 3- and 6-month test samples of two pa-
tients (No. 8 and 9), were both clearly indicated by both
dogs. For one additional patient (No. 3), the 3-month
sample was indicated by both dogs while the 6-month
sample was clearly indicated by Hanna and uncertainly
indicated by Lotti. All three patients had recurrences, and
two of them died 3–4 years after the end of treatment.
The January 2013 record check showed that two of the 10
patients (No. 8 and 9) included in Series II who were
thought to be recurrence-free during the first 3 years after
treatment, had in fact relapsed a few months before 3 years
had passed. The reason they were categorized as having
no relapse was that the database had not been updated at
the time of patient selection, and their current recurrence
was not known to us.
Six-month test samples from two patients (No. 2 and 10)
were clearly indicated by the two dogs, but the patients
remained relapse-free 4 years after completion of treat-
ment. The dogs’ indications in those cases were fairly
consistent, which may imply an increased risk of recurrence
in future years.
The remaining indications were consistent with patient
survival, although in some cases (e.g., No. 1 and 4) there
were suggestions by uncertain indication behavior that
there may be a few viable cancer cells remaining in theTable 5 Tumor characteristics, dog responses, and survival fo
No Test samples
3 m/6 m
Diagnosis date Stage Histopathology
1 4842/5095 Feb 2009 III/C Seropapillary
2 3932/4799 June 2008 III/C Seropapillary
3 406/1018 Nov 2005 III/C Adenocarcinoma
4 9807/108 Jan 2005 II/C Adenocarcinoma
5 8647/8955 Dec 2003 III/C Clear cell
6 10704/1328 Dec 2005 II/C Seropapillary
7 451/1065 Sept 2005 III/C Undifferentiated
8 3835/6750 Feb 2000 III/C Seropapillary
9 6132/7872 Jan 2004 II/C Seropapillary
10 4926/5214 Aug 2008 II/B Seropapillary
* = all CA-125 values were <35UI.
Dog responses:
X = positive indication as cancer; O = no indication; # = uncertain indication.body. It is likely that in several cases the concentration of
typical odor molecules was near the lower limit of canine
detection ability. To estimate what this limit might be, we
have previously published results showing that one dog
(Hanna) was repeatedly able to identify with certainty
a piece of fatty abdominal wall containing about 20
microscopically-verified ovarian cancer cells [6]. It is
impressive how this very low limit of detection allows
dogs to signal probable future recurrences that would not
be diagnosed by other methods for another 2–3 years.
This is the most important result of the present study.
The dogs were able to indicate small numbers of living
cancer cells with high sensitivity and specificity in a large
group of ovarian cancer patients. To our knowledge;
this is the first study to highlight the importance of
characteristic odor molecules in the blood of ovarian
cancer patients as a prognostic marker. Previously,
McCulloch et al. described one patient with breast can-
cer in remission who was identified by dogs as having
cancer [2]. Detection of odor in the blood, currently
only possible with trained dogs, can allow for early and
long-term prediction of survival. An early diagnosis of
primary or recurrent disease may also significantly improve
the patient’s survival.
Conclusion
In summary, although our results are based on a limited
number of patients, they clearly show that canine
detection gave us a very good opportunity to assess the
prognosis of the study patients Being able to detect a
marker based on the specific cancer odor in the blood
would enhance both primary diagnosis and relapse
diagnosis. An instrument with a sensitivity and specificity
close to that of the trained dogs used here is necessary for





Case record Jan 2013
2 O O X # Alive/relapse-free
3 O X X X Alive/relapse-free
3 X X # X Relapse 2008/Died 2009
2 O X O # Alive/relapse-free
2 X X O X alive/relapse-free
3 # O O # Alive/relapse-free
4 X X O # Relapse 2009/alive
3 X X X X Relapse 2002/died 2005
2 X X X X Relapse 2006/alive
2 O # X X Alive/relapse-free
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